Alloy Medical Leadership and Credentials: An Independent Review for Women

What Alloy Is and Who It Is Built For

Alloy positions itself as a menopause-focused telehealth company delivering hormone replacement therapy, topical hair-loss treatments, and sexual health products directly to women across the United States. The model is cash-pay and asynchronous: you complete an intake questionnaire, a licensed clinician reviews it, and a prescription is sent to a partner pharmacy if appropriate.

The company's stated target population is women in perimenopause and postmenopause who want faster access to care than a traditional OB-GYN or primary-care appointment allows. According to The Menopause Society, roughly 1.3 million women in the United States reach menopause each year, a figure that captures only a fraction of the larger perimenopausal cohort who are actively experiencing symptoms but often waiting months for specialist appointments.

That access gap is real. It is also exactly the kind of unmet need that invites companies to build quickly, sometimes faster than clinical infrastructure can keep pace.

Who the Platform Is Not Built For

Alloy's asynchronous model has structural limits. Women with complex histories, including prior breast cancer, active cardiovascular disease, unexplained vaginal bleeding, or a personal history of VTE (venous thromboembolism), are not good candidates for any asynchronous-only prescribing pathway. ACOG Practice Bulletin 141 specifies that menopausal hormone therapy requires individualized risk-benefit assessment, which is difficult to conduct without a synchronous clinical encounter for high-risk patients.

If you fall into any of those categories, an in-person clinician or at minimum a live video visit with a menopause specialist is the appropriate first step.

Alloy's Medical Leadership: What Is Publicly Verifiable

This is where candor matters most. Alloy's public-facing website, as of mid-2025, does not prominently list a named Chief Medical Officer or a full medical advisory board with verifiable credentials. This is a meaningful gap compared to competitors that publish named physicians, board certifications, and institutional affiliations.

What the Company Does State

Alloy states that prescriptions are written by licensed physicians and nurse practitioners who are authorized to practice in the patient's state. This is legally required for any telehealth platform operating in the United States, so it is a floor, not a differentiator.

State medical boards govern individual prescribers. If you want to verify your specific prescriber, you can look them up on your state's medical board website. The Federation of State Medical Boards maintains a DocInfo search tool that aggregates licensure data, though for the most current status you should go directly to your state board.

The Evidence Gap on Oversight

No published audit of Alloy's internal clinical review processes, prescribing protocols, or quality-assurance procedures is publicly available. The company has not, as of this writing, published a clinical white paper, peer-reviewed outcomes data, or a named IRB-approved study of its patient population.

Here is a framework for evaluating any telehealth menopause platform before you sign up:

1. Named medical leadership. Can you find a Chief Medical Officer or medical director with a verifiable license number and board certification in reproductive endocrinology, OB-GYN, or a relevant specialty?
2. Published prescribing protocols. Does the company share, at minimum, which clinical guidelines it follows? The 2023 Menopause Society Position Statement on Hormone Therapy is the current standard.
3. Synchronous escalation pathway. Can you actually speak to a clinician, not just message one, if your symptoms change or a side effect concerns you?
4. Transparent pharmacy partnerships. Is the compounding or dispensing pharmacy FDA-registered? Is it PCAB-accredited?
5. Complaint resolution process. Is there a documented process for resolving clinical disputes, not just subscription cancellations?

Alloy meets the legal minimum on point one (licensed prescribers in your state) but does not clearly satisfy points two through five based on publicly available information. That does not make the platform unsafe for every woman, but it does mean you should ask these questions directly before starting.

The Drugs Alloy Prescribes: What Women Need to Know

Alloy primarily offers estradiol-based hormone therapy, low-dose vaginal estrogen, and topical progesterone or oral micronized progesterone for women with an intact uterus. It also offers topical minoxidil and finasteride for female hair loss, and sildenafil or other agents for sexual health in some states.

Hormone Therapy

Systemic estrogen is the most effective treatment for vasomotor symptoms of menopause. A landmark 2017 meta-analysis published in JAMA Internal Medicine confirmed that oral and transdermal estrogen significantly reduce hot flash frequency and severity compared with placebo, with transdermal routes showing a more favorable VTE profile than oral formulations.

The 2023 Menopause Society position statement concludes that for healthy women under age 60, or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for the treatment of vasomotor symptoms and prevention of bone loss. That framing matters because many women are still told, incorrectly, that hormone therapy is uniformly dangerous based on a misreading of the Women's Health Initiative.

The Women's Health Initiative, published in the New England Journal of Medicine in 2002, enrolled women with a mean age of 63. Applying those findings to women in their late 40s or early 50s who are newly menopausal is an extrapolation, not a direct comparison.

Sex-Specific Pharmacokinetics

Estradiol absorption, distribution, and metabolism differ meaningfully between women depending on hormonal status and route of administration. Transdermal estradiol bypasses first-pass hepatic metabolism, which is why it carries a lower risk of raising triglycerides and a lower VTE risk than oral estradiol. A 2019 study in the BMJ found that transdermal estradiol was not associated with increased VTE risk, while oral estrogen was, particularly at higher doses.

Body weight also affects estradiol levels. Women with higher BMI may have different circulating estradiol levels on a standard dose, which is one reason that dose titration, ideally with follow-up lab testing, matters. Whether Alloy's asynchronous model consistently incorporates serum estradiol monitoring is not clearly documented.

Progesterone and Uterine Protection

Any woman with an intact uterus who takes systemic estrogen must also take a progestogen to protect the uterine lining. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. ACOG Practice Bulletin 141 is explicit on this point.

Oral micronized progesterone (Prometrium 200 mg nightly for 12 days per cycle, or 100 mg nightly continuously) is the preferred progestogen for most women because of its more favorable cardiovascular and breast-cancer risk profile compared with synthetic progestins. If Alloy is prescribing combined therapy, confirming which progestogen and what schedule is part of your due diligence.

Pregnancy, Lactation, and Contraception: A Required Disclosure

Menopausal hormone therapy products are contraindicated in pregnancy. This is not a theoretical caution. Estrogen and progesterone preparations used for menopause are not appropriate for use during pregnancy, and systemic estrogen exposure in early pregnancy carries potential fetal risk.

Because perimenopause does not equal infertility, women in their 40s who are not yet confirmed postmenopausal (defined as 12 consecutive months without a menstrual period) can still conceive. If you are perimenopausal and sexually active with a male partner, you need reliable contraception while using hormone therapy.

ACOG recommends that women in perimenopause continue contraception until menopause is confirmed. Low-dose combined oral contraceptives or progestin-only pills can serve dual purposes in this life stage: symptom management and contraception.

Finasteride and Pregnancy

If Alloy prescribes finasteride for female hair loss, this is a category X agent in pregnancy. FDA labeling for finasteride states that finasteride is contraindicated in women who are or may become pregnant because of the risk of feminization of a male fetus. Women of reproductive age who are prescribed finasteride must use reliable contraception for the duration of treatment.

Lactation

Systemic estrogen suppresses lactation and is generally avoided in breastfeeding women. Low-dose vaginal estrogen has minimal systemic absorption and may be considered postpartum after lactation has ceased, but this discussion belongs in a clinical encounter, not an intake form.

Alloy's Hair Loss and Sexual Health Offerings

Female Hair Loss

Alloy offers topical minoxidil and, in some states, oral minoxidil and finasteride for female pattern hair loss (androgenetic alopecia). Female pattern hair loss affects approximately 40% of women by age 50, and PCOS is one of the most common underlying drivers in reproductive-age women due to androgen excess.

Topical minoxidil 2% and 5% are FDA-approved for female pattern hair loss. A Cochrane review of minoxidil for hair loss found that 5% topical minoxidil produced greater hair regrowth than 2% in women, though scalp irritation was more common at the higher concentration.

Finasteride for female hair loss is used off-label. The evidence in postmenopausal women is more studied than in premenopausal women. A 2006 RCT in the Journal of the American Academy of Dermatology found no significant benefit of finasteride 1 mg daily over placebo in postmenopausal women with androgenetic alopecia, which is a notable finding that many direct-to-consumer platforms do not acknowledge.

Sexual Health

Alloy offers products for hypoactive sexual desire disorder (HSDD) and genitourinary syndrome of menopause (GSM). GSM, formerly called vaginal atrophy, affects an estimated 50-60% of postmenopausal women and is significantly undertreated. Low-dose vaginal estradiol or vaginal DHEA (prasterone) are first-line treatments supported by The Menopause Society.

Whether Alloy's sexual health intake process screens adequately for relationship factors, psychological contributors to HSDD, or medication-induced sexual dysfunction (SSRIs, beta-blockers, and antihypertensives are common offenders in midlife women) is not clear from public information.

Complaint History and Regulatory Record

Better Business Bureau

As of mid-2025, Alloy is not accredited by the Better Business Bureau. BBB accreditation is voluntary and its absence does not indicate wrongdoing, but it does mean the company has not submitted to BBB's standards for responsiveness and transparency. Complaints filed with the BBB against Alloy, which you can review at bbb.org, have cited billing and subscription cancellation difficulties, delayed prescriptions, and limited access to a live clinician.

FDA and LegitScript

LegitScript is the primary independent certification body for online pharmacies and telehealth platforms in the United States. A LegitScript-certified designation signals that a platform meets pharmacy practice standards and does not dispense controlled substances without appropriate oversight. Alloy's LegitScript status should be independently verified directly on the LegitScript website before you use the platform.

The FDA does not regulate telehealth companies directly as entities, but it does regulate the drugs and pharmacy practices involved. Compounded hormones dispensed through telehealth platforms are subject to FDA oversight under the Federal Food, Drug, and Cosmetic Act. FDA guidance on compounded drug products makes clear that compounded bioidentical hormones are not FDA-approved and have not been evaluated for safety and efficacy in the same way as approved drugs.

State Medical Board Oversight

Individual prescribers working for Alloy are subject to their state medical board's jurisdiction. If you experience a clinical concern, a prescribing error, or feel that your intake was inadequate, you can file a complaint with the state board of the prescribing clinician. The prescriber's name and license number should appear on your prescription.

Who This Platform May Suit and Who Should Look Elsewhere

Life Stages and Situations Where Alloy May Be a Reasonable Starting Point

• Postmenopausal women (confirmed, 12-plus months without periods) with classic vasomotor symptoms and no significant cardiovascular, thromboembolic, or cancer history
• Perimenopausal women who have already had a recent in-person exam and baseline labs and want a convenient refill pathway
• Women with female pattern hair loss who have already ruled out thyroid disease, iron deficiency, and PCOS with a clinician
• Women experiencing GSM who want low-dose vaginal estrogen and have no contraindications

Life Stages and Situations Where You Need More Than Alloy Can Offer

• Women in reproductive years with active fertility goals (HRT is not appropriate; fertility workup requires specialist care)
• Postpartum women, particularly those breastfeeding
• Women with a personal or family history of hormone-sensitive cancers, including breast cancer and endometrial cancer
• Women with a prior VTE or known thrombophilia
• Women with unexplained vaginal bleeding, which requires in-person evaluation to rule out endometrial pathology before any estrogen is prescribed
• Women with PCOS who need androgen management, metabolic assessment, and cycle regulation, not just hair-loss prescriptions
• Perimenopausal women who are not yet confirmed as postmenopausal and need contraception counseling alongside symptom management

What the Evidence Base Actually Supports

A frequently overlooked reality in the direct-to-consumer menopause space is that the clinical trials supporting hormone therapy were conducted predominantly in women who had in-person evaluations, physical exams, and baseline laboratory testing before enrollment. The KEEPS trial, which studied low-dose oral and transdermal estrogen in recently menopausal women, and the ELITE trial, which examined the timing of HRT initiation on cardiovascular outcomes, both required rigorous screening.

Extrapolating those findings to an asynchronous telehealth model, where no one has examined your uterus, checked your blood pressure, or reviewed recent mammography results, is a step that deserves explicit acknowledgment. This does not mean telehealth HRT is unsafe. It means the safety data was generated in settings with more clinical touchpoints than a questionnaire.

As The Menopause Society's 2023 position statement puts it: "An individualized approach to treatment decisions is essential." An intake form is a starting point, not a substitute for that individualization.

Practical Steps Before You Start With Alloy or Any Telehealth Menopause Platform

1. Request the name, license number, and state of your prescribing clinician before your prescription is sent. Verify that license on your state board's website.
2. Ask the platform directly which clinical guidelines it uses for prescribing decisions. The answer should reference the 2023 Menopause Society position statement or ACOG Practice Bulletin 141.
3. Confirm whether your pharmacy is FDA-registered and, if compounded hormones are involved, whether the compounding pharmacy is PCAB-accredited.
4. If you have any of the contraindications listed above, insist on a synchronous (live video or phone) visit before any prescription is issued.
5. Get a baseline pelvic exam and mammogram on schedule with your in-person provider. Telehealth does not replace those.
6. Keep your primary-care clinician or OB-GYN informed of any prescriptions you receive through telehealth platforms so your full medication list is accurate.

If Alloy cannot answer questions one through three directly and specifically, that is a clinical red flag, not a subscription billing problem.